Camidanlumab tesirine  (Synonyms: ADCT 301)

Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines^[1].

Camidanlumab tesirine (ADCT 301; 3, 10 ng/mL; 48 hours) resultes in a dose-dependent G2-M arrest reaching a maximum at 48 hours^[1].
Camidanlumab tesirine (10 ng/mL; 24-96 hours) induces apoptosis^[1].
Camidanlumab tesirine has the GI₅₀ values ranged from 0.04-2.94 ng/mL in the CD25-positive lines. GI₅₀ values in the CD25-negative lines are >1,000 ng/mL. The nonbinding ADC gives GI₅₀ values >1,000 ng/mL in both antigen-expressing and nonexpressing lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Camidanlumab tesirine (ADCT 301; 0.1-0.6 mg/kg/day; iv; 60 days) delayed tumor growth in a dose-dependent fashion^[1].
Camidanlumab tesirine has the half-life of 7.3 days by analysis of the conjugated antibody with DAR component ≥1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1853239-04-9

Liquid

Colorless to light yellow

[Camidanlumab tesirine]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2709-2721.  [Content Brief]

  [2]. Francesca Zammarchi, et al. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8(2):e000860.  [Content Brief]